Bank of Japan Officials Signal Continued Interest Rate Hikes Amid Inflation Concerns 
Sonova Shares Slip as Hearing Aid Giant Lowers Growth Outlook and Plans Sennheiser Exit 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Rio Tinto's Resolution Copper Mine: U.S. Smelting Challenges and Global Operations Update 
NASA and Roscosmos Chiefs Meet in Florida to Discuss Moon and ISS Cooperation 
U.S. Stock Futures Steady as Iran Reviews U.S. Ceasefire Proposal 
Air Canada Express Crash at LaGuardia: Controller Distracted by Prior Emergency 
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant 
SMIC Allegedly Supplies Chipmaking Tools to Iran's Military, U.S. Officials Warn 
CK Hutchison's Panama Ports Dispute Escalates as Arbitration Claims Surpass $2 Billion 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil 
Golden Dome Missile Defense: Anduril and Palantir Join Forces on Trump's $185B Space Shield 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
Japan Eyes Oil Futures Intervention to Stabilize Yen Amid Middle East Crisis 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
South Korea’s JW Pharmaceutical has received a patent in Russia for a hair loss treatment currently under development, marking the first time that its candidate drug has been patented overseas.
The pharmaceutical firm received a patent for JW0061, its Wnt-targeted hair loss treatment, from Russia's Federal Service for Intellectual Property.
The patent covers a new heterocyclic inducer of the Wnt signaling pathway, including its base or isomer, and compositions containing it as an active ingredient.
JW has also submitted patent applications in more than ten nations, including the US, EU, Japan, and China.
JW0061 exhibits a novel method of action by directly binding to the GFRA1 protein in human hair dermal papilla cells, activating the Wnt signaling pathway. This is the first instance of a low-molecular-weight medication that describes the mechanism of hair growth that has been documented.
JW is now evaluating non-clinical toxicity in accordance with good laboratory practice with the intention of initiating clinical trials for JW0061 in the first half of 2024. Additionally, it collaborates on research projects with eminent dermatologists in the US.
JW plans to develop JW0061 as a new innovative drug that supplements or replaces existing hair loss treatments.
